Leaders in Cognitive Measurement

At Cogstate, we believe brain health is profoundly important to quality of life and should be easier to measure.

Therefore, our mission is to optimize cognitive assessments to support the development of new therapeutics and provide earlier brain health insights in clinical care.

For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. We provide rapid, reliable and highly sensitive computerized cognitive tests and support electronic clinical outcome assessment (eCOA) solutions. We also offer quality assurance services for clinical trial endpoints that combine innovative operational approaches, advanced analytics and scientific consulting.

Our Solutions

Cogstate combines core capabilities of science, technology and operational expertise in three key vertical market segments

Clinical Trials

Services and solutions to accelerate drug development decision-making regarding the safety and efficacy of therapeutic candidates


Regulatory cleared medical device to detect cognitive impairment and change in patients

Academic Research

Solutions for researchers studying cognition, from academics to major public-private partnerships

Cogstate Group

The Cogstate Group comprises Cogstate Ltd and six subsidiaries that are all directly or indirectly wholly owned.



Cogstate was founded in 1999 when a group of neuroscientists in Australia worked with angel investors to create the first code base. The initial idea for a computerized cognitive assessment came while Cogstate’s first scientists were working with indigenous communities in central Australia. There they discovered that assessments of cognition were limited by both linguistic and cultural contexts. Seeking to address these challenges, our scientists developed assessments of cognition that were largely free of language, were culturally neutral and could be used to identify impairments and changes in cognition in any group of individuals.

Cogstate achieved initial sales in sports medicine, using the technology to determine if an athlete’s cognitive performance had changed from his or her baseline as a result of concussive injury. To this day, Cogstate supports thousands of athletes, both amateur and professional, worldwide.

Cogstate grew substantially when we began working with pharmaceutical companies as part of their clinical trials of investigational therapeutics; today most of our staff support these efforts. Through our work, we have been fortunate to play a role in the approval of new therapeutics, including those for depression, schizophrenia, and bipolar disorder.


Cogstate has gathered strong scientific validation of our tests through more than 400 peer-reviewed studies showing their sensitivity and specificity. The tests have been leveraged in more than 2,000 academic and clinical trial studies across 70 indications as measures of both safety and efficacy.

In addition, Cogstate supports conventional, paper-and-pencil measures of cognition. In this realm, we leverage technology, such as eCOA, to support the collection of data and provide quality control solutions for these rater-administered assessments via rater training and central monitoring solutions. We have trained thousands of raters and supported sites worldwide.

Office Locations

Cogstate has 3 primary offices in the following locations:

United States

195 Church Street, 4th Floor
New Haven, CT 06510

1350 Broadway, Suite 1620
New York, NY 10018


Suite 117
425 Smith Street
Fitzroy VIC 3065 Australia